HHS Raises Profile In Drug Costs Discussion
This article was originally published in The Pink Sheet Daily
On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.
You may also be interested in...
The two big pharmas are the only representatives of branded drug manufacturers scheduled to participate in the meeting. GPhA’s Chip Davis is on the agenda to represent the generic drug industry's point of view.
Acting Administrator Andy Slavitt explains CMS is in information-gathering mode as it considers ways of addressing accelerating drug costs in Medicare and Medicaid.
Industry group is promoting policy changes such as allowing broader communications with payers and a safe harbor for patient adherence programs that may help manufacturers and payers negotiate outcomes-based contracts for biopharma products.